Prudential Financial Inc. lessened its holdings in Retrophin Inc (NASDAQ:RTRX) by 10.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 332,516 shares of the biopharmaceutical company’s stock after selling 38,427 shares during the period. Prudential Financial Inc. owned approximately 0.81% of Retrophin worth $9,554,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also made changes to their positions in the company. Trexquant Investment LP acquired a new position in shares of Retrophin in the 2nd quarter valued at $273,000. Sei Investments Co. acquired a new position in shares of Retrophin in the 2nd quarter valued at $141,000. Algert Global LLC purchased a new stake in shares of Retrophin in the 2nd quarter valued at $358,000. PNC Financial Services Group Inc. raised its holdings in shares of Retrophin by 1,404.9% in the 2nd quarter. PNC Financial Services Group Inc. now owns 272,328 shares of the biopharmaceutical company’s stock valued at $7,424,000 after buying an additional 254,232 shares during the period. Finally, Jennison Associates LLC raised its holdings in shares of Retrophin by 1.3% in the 2nd quarter. Jennison Associates LLC now owns 1,070,327 shares of the biopharmaceutical company’s stock valued at $29,177,000 after buying an additional 14,166 shares during the period.
RTRX stock opened at $23.85 on Wednesday. The company has a current ratio of 5.04, a quick ratio of 4.99 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $1.01 billion, a P/E ratio of -15.90 and a beta of 1.19. Retrophin Inc has a 12-month low of $20.09 and a 12-month high of $33.00.
Retrophin (NASDAQ:RTRX) last posted its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.39). The firm had revenue of $40.70 million during the quarter, compared to analysts’ expectations of $44.36 million. Retrophin had a negative net margin of 69.38% and a negative return on equity of 35.43%. Retrophin’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.15 EPS. On average, research analysts expect that Retrophin Inc will post -2.67 EPS for the current year.
In other Retrophin news, SVP Elizabeth E. Reed sold 2,500 shares of the company’s stock in a transaction dated Wednesday, November 14th. The stock was sold at an average price of $23.73, for a total transaction of $59,325.00. Following the sale, the senior vice president now owns 20,627 shares in the company, valued at approximately $489,478.71. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Steve Aselage sold 11,100 shares of the company’s stock in a transaction dated Thursday, November 15th. The stock was sold at an average price of $24.03, for a total value of $266,733.00. Following the sale, the chief executive officer now owns 259,433 shares in the company, valued at approximately $6,234,174.99. The disclosure for this sale can be found here. Insiders sold a total of 36,100 shares of company stock worth $863,658 in the last quarter. Company insiders own 3.67% of the company’s stock.
Several equities research analysts recently issued reports on the company. Nomura assumed coverage on Retrophin in a report on Monday, November 19th. They issued a “buy” rating and a $57.00 price objective on the stock. Canaccord Genuity assumed coverage on Retrophin in a report on Friday, August 17th. They issued a “buy” rating on the stock. BidaskClub upgraded Retrophin from a “hold” rating to a “buy” rating in a report on Tuesday, August 28th. Zacks Investment Research upgraded Retrophin from a “sell” rating to a “hold” rating in a report on Thursday, September 27th. Finally, ValuEngine upgraded Retrophin from a “buy” rating to a “strong-buy” rating in a report on Wednesday, November 7th. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Retrophin currently has an average rating of “Buy” and an average target price of $48.00.
TRADEMARK VIOLATION WARNING: “Retrophin Inc (RTRX) Stake Lowered by Prudential Financial Inc.” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/12/05/retrophin-inc-rtrx-stake-lowered-by-prudential-financial-inc.html.
Retrophin, Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Recommended Story: Why do corrections happen?
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.